Bridgetech Opens Taiwan Office
"The value of the Taiwan market is tremendous," stated Michael Chermak,Chairman and CEO of Bridgetech. "The alliances with Taiwan's governmentalbodies, medical research institutes, medical providers and leading companieslike Formosa are allowing the company to quickly ramp up our technologytransfer initiatives."
John Chen, President of Bridgetech Medicines Limited, added "We're pleasedto bring CellSearch to Taiwan's oncology market. In addition, Bridgetech'sbase in Taiwan allows an ongoing evaluation and introduction of current andfuture products in our pipeline."
About Bridgetech Holdings International, Inc.
Bridgetech is leveraging its extensive network of relationships in Chinaand the U.S. to capitalize on the demand for Western healthcare in GreaterChina. The company is bringing emerging drugs, devices and diagnostics toGreater China, with an initial focus on oncology. For additional information,please visit Bridgetech at http://www.bthi.com .
Statements contained in this press release that are not statements ofhistorical fact are "forward-looking statements" as that term is defined underfederal securities laws, including, without limitation, all statementsconcerning expectations, beliefs, goals, intention or strategies for thefuture of Bridgetech. Forward-looking statements may be identified by wordssuch as "goals," "plans," "believes," "will," "expects" and other words ofsimilar meaning used in conjunction with, among other things, discussions offuture operations, financial performance, product development and new ventures.Many factors could cause actual events or results to differ materially fromthose expressed in any forward-looking statement. Investors are cautioned notto place any undue reliance on any forward-looking statements.Bridgetech Medicines LimitedRoom WR05., 17th floor, 3 YuanQu St., Taipei 115, Taiwan Tel: 02-2653-9013 Fax: 02-2653-8047
SOURCE Bridgetech Holdings International Inc.
You May Also Like